Dianthus Therapeutics Inc. DNTH
Super Investor & Insider
1
Fondi che lo detengono
#1460
Rank consenso
1.4%
% dei portafogli
$345,666
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Polen Capital Management · Polen Capital Management | 0% | Buy | 4,119 | $345,666 |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases. It designs and delivers novel monoclonal antibodies and biologics with enhanced selectivity, potency, and dosing convenience c…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees78
TickerDNTH
Statistics
Market Cap$4.44B
Revenue (TTM)$2.0M
Net Income-$162.3M
Net Margin-7973.3%
EPS$-4.20
P/E3.30
P/S3126.94
P/B3.47
EV/EBITDA-16.05
ROE-22.7%
Dividend Yield—
Price$81.42
Data: Twelve Data · Revenue = mcap / P/S